Antitumor vaccination: Where we stand

Haematologica

Volumn 85, Issue 11, 2000, Pages 1172-1206

  Bocchia, M ^a   Bronte, V ^a   Colombo, M P ^a   De Vincentiis, A ^a   Di Nicola, M ^a   Forni, G ^a   Lanata, L ^a   Lemoli, R M ^a   Massaia, M ^a   Rondelli, D ^a   Zanon, P ^a   Tura, S ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Antitumor vaccination

Indexed keywords

CANCER ANTIBODY;

ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CHRONIC MYELOID LEUKEMIA; COLON CANCER; CYTOTOXICITY; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; KIDNEY CARCINOMA; LYMPHOPROLIFERATIVE DISEASE; MELANOMA; PROSTATE CANCER; REVIEW; T LYMPHOCYTE; VACCINATION; VIRUS RECOMBINANT;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS; HUMANS;

EID: 0033658977     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (278)

1. Cell therapy: Achievements and perspectives
2. The immunological principles of vaccination
3. Lifespan of naive, memory and effector lymphocytes
4. Vaccine technologies: View to the future
5. Innate immunity: The virtues of a nonclonal system of recognition
6. Tolerance, danger, and the extended family
7. Cytokines, tumor-cell death and immunogenicity: A question of choice
8. Cancer vaccines: A road map for the next decade
9. The histocompatibility systems
10. Intradermal immunization of C3H mice against a sarcoma that originated in an animal of the same line
11. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host
12. Murine tumor antigens: Is it worth the search?
13. A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumors of spontaneous origin
14. Antigenic tumor cell variants obtained with mutagens
15. Immunogenic (tum-) variants of mouse tumor P185: Cloning the gene of tum- antigen P91A and identification of the tum- mutation
16. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E
17. Human tumour antigens recognized by T cells: New perspectives for anti-cancer vaccines?
18. Human tumor antigens recognized by T cells
19. The case history of Mr. T.I. - Terminal patient or still curable
20. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes
21. Identifying strategies for immune intervention
22. Immunotherapy I: Cytokine gene transfer strategies
23. Specific and nonspecific immunity in the prevention of spontaneous tumours
24. Cytokine gene therapy: Hopes and pitfalls
25. Cytokine gene transfer in tumor inhibition and tumor therapy: Where are we now?
26. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL6, IL-7, IL-10, tumor necrosis factor α, granulocyte-macrophage colony-stimulating factor, and γ-interferon gene or admixed with conventional adjuvants
27. Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12
28. Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin 12
29. Signals and signs for lymphocyte responses
30. Dendritic cells and the control of immunity
31. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells
32. Direct and indirect T cell priming by dendritic cell vaccines
33. Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses
34. Molecular approaches to cancer immunotherapy
35. FLT3-ligand administration inhibits liver metastases: Role of NK cells
36. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer
37. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma
38. Vaccination with IL-12 gene-modified autologous melanoma cells: Preclinical results and a first clinical phase I study
39. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates
40. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
41. CD4(+) T cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD40L:CD154) antibody lose their graft-versus-host disease lethality capacity but retain nominal antigen responses
42. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy
43. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40
44. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells
45. Enhancement of antitumor immunity by CTLA-4 blockade
46. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: The effect is manifested only at the restricted tumor-bearing stages
47. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation
48. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma
49. Dendritic cells: Expansion and differentiation with hematopoietic growth factors
50. Coordinated events during bacteria-induced DC maturation
51. The paradigm of type 1 and type 2 antigen presenting cells. Implications for atopic allergy
52. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation
53. Reciprocal control of T helper cell and dendritic cell differentation
54. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor
55. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function
56. Critical role of IL-12 in dendritic cell-induced differentiation of naive B lymphocytes
57. Recent advances in the study of dendritic cells and follicular dendritic cells
58. Cytokine gene transfer in cancer therapy
59. Hypoxic tumor cell death and modulation of endothelial adhesion molecules in the regression of granulocyte colony-stimulating factor-transduced tumors
60. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells
61. Selective proteasome inhibitors: Modulators of antigen presentation?
62. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine
63. Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside
64. Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases
65. Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine
66. Human tumor antigens recognized by T lymphocytes
67. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens
68. Establishment of a tumor-specific immunotherapy model utilizing TNP-reactive helper T cell activity and its application to the autochthonous tumor system
69. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α
70. Functions of CD40 on B cells, dendritic cells and other cells
71. Dendritic cells infiltrating tumors cotransduced with granulocyte-macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response
72. Resurrecting the dead: DCs cross-present antigen derived from apoptotic cells on MHC I
73. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression
74. Heat shock proteins come of age: Primitive functions acquire new roles in an adaptive world
75. Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients
76. Specificity analysis of sera from breast cancer patients vaccinated with MUC1-KLH plus QS-21
77. Liposomal formulation of a self lymphoma antigen induces protective antitumor immunity
78. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors
79. Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity
80. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma: Long-term results of a clinical trial
81. Characterization of a nontoxic monophosphoryl lipid A
82. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination
83. Cell biology of antigen processing and presentation to major histocompatibility complex class I molecule-restricted T-lymphocytes
84. Antigen presentation
85. Supply and transport of peptides presented by class I MHC molecules
86. Chemistry of peptides associated with MHC class I and class II molecules
87. Antigen presentation: Structural themes and functional variations
88. MHC-dependent antigen processing and peptide presentation: Providing ligands for T lymphocyte activation
89. MHC: Orchestrating the immune response
90. MHC ligands and peptide motifs: First listing
91. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules
92. Assessment of major histocompatibility complex class I interaction with Epstein-Barr virus and human immunodeficiency virus peptides by elevation of membrane H-2 and HLA in peptide loading-deficient cells
93. The relationship between class I binding affinity and the immunogenicity of potential cytotoxic T cell epitopes
94. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes
95. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp 100 modified at HLA-A*0201-binding residues
96. Diversity of the fine specificity displayed by HLA-A*0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide
97. Changes in the fine specificity of gp 100(209-217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue
98. A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors
99. Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11
100. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen
101. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules
102. Two bcr-abl junction peptides bind to HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes
103. Specific human cellular immunity to BCR-ABL oncogene-derived peptides
104. Recognition of BCR-ABL positive leukemia blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide
105. HLA-DR1-restricted bcr-abl (b3a2)-specific CD4+ T lymphocytes respond to dendritic cells pulsed with b3a2 peptide and antigen-presenting cells exposed to b3a2 containing cell lysates
106. Characterization of a naturally processed MHC class II-restricted T-cell determinant of hen egg lysozyme
107. Identification of T-cell epitopes: Rapid isolation of class-I presented peptides from viable cells by mild acid elution
108. Wild-type p53 epitope naturally processed and presented by an HLA-B haplotype on human breast carcinoma cells
109. Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp 100
110. Antileukemic HLA-restricted T-cell clones generated with naturally processed peptides eluted from acute myeloblastic leukemia blasts
111. Naturally processed tissue- and differentiation stage-specific autologous peptides bound by HLA class I and II molecules of chronic myeloid leukemia blasts
112. Cancer immunotherapy: Synthetic and natural peptides in the balance
113. T-cell recognition of human melanoma antigens
114. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
115. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression
116. Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes
117. Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4+ T cells
118. BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors
119. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia
120. A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma
121. Tumor regressions observed 'in patients with metastatic melanoma treated with an antigenic peptide encoded bygene MAGE-3 and presentedby HLA-A1
122. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses
123. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7
124. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells
125. Helper-cytotoxic T lymphocytes (CTL) determinant linkage required for priming of anti-HIV CD8+CTL in vivo with peptide vaccine constructs
126. Immune responses in the absence of costimulation: Viruses know the trick
127. Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates
128. A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): Safety and immunogenicity in a nonhuman primate
129. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases
130. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine
131. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine
132. Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines
133. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: Enhancement by simultaneous B7-1 expression
134. Construction and characterization of a triple-recombinant vaccinia virus encoding B7-1, interleukin 12, and a model tumor antigen
135. Recombinant virus vaccination against 'self' antigens using anchor-fixed immunogens
136. Vaccination with a recombinant vaccinia virus encoding a 'self' antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement fot CD4(+) T lymphocytes
137. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine
138. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen
139. Toxicological comparison of E2a-deleted and first-generation adenoviral vectors expressing alpha1-antitrypsin after systemic delivery
140. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens
141. Potential use of non-replicating vectors as recombinant vaccines
142. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen
143. Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein
144. Poxvirus-based vaccine candidates for cancer, AIDS, and other infectious diseases
145. Experiences with immunization against orthopox viruses of humans and animals using vaccine strata MVA
146. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: A murine tumor model
147. Enhanced immunogenicity for CD8+ Tcell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara
148. Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity
149. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL
150. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens
151. Gene transfer into human dendritic antigen-presenting cells by vaccinia virus and adenovirus vectors
152. Heterologous protection against influenza by injection of DNA encoding a viral protein
153. DNA vaccines
154. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine
155. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients
156. Salmonella vaccine carrier strains: Effective delivery system to trigger anti-tumor immunity by oral route
157. Gene transfer in dendritic cells, induced by oral DNA vaccination with Salmonella typhimurium, results in protective immunity against a routine fibrosarcoma
158. Delivery of a viral antigen to the class I processing and presentation pathway by Listeria monocytogenes
159. Synergistic effect of formulated plasmid and needle-free injection for genetic vaccines
160. Influenza virus nucleoprotein-specific immunoglobulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery
161. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization
162. CpG motifs in bacterial DNA trigger direct B-cell activation
163. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma
164. Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha
165. CpG motifs as immune adjuvants
166. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization
167. CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells
168. Differential dependence on target site tissue for gene gun and intramuscular DNA immunizations
169. The dominant role of bone marrow-derived cells in CTL induction following plasmid DNA immunization at different sites
170. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization
171. DNA vaccination: Transfection and activation of dendritic cells as key events for immunity
172. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases
173. Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice
174. CTL response and protection against P815 tumor challenge in mice immunized with DNA expressing the tumor-specific antigen P815A
175. DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors
176. Coupling and uncoupling of tumor immunity and autoimmunity
177. Tumor immunity and autoimmunity induced by immunization with homologous DNA
178. Genetic vaccination with 'self' tyrosinase-related protein 2 causes melanoma eradication but not vitiligo
179. Alphavirus expression systems
180. Cancer therapy using a self-replicating RNA vaccine
181. Dendritic cells freshly isolated from human blood express CD4 and mature into typical immunostimulatory dendritic cells after culture in monocyte-conditioned medium
182. A novel cell-surface molecule expressed by human interdigitating reticulum cells, Langerhans cells, and activated lymphocytes is a new member of the IG superfamily
183. Circulating human dendritic cells differentially express high levels of a 55-kd actin-bundling protein
184. Interactions of tumor necrosis factor with granulocyte-macrophage colony-stimulating factor and other cytokines in the regulation of dendritic cell growth in vitro from early bipotent CD34+ progenitors in human bone marrow
185. Expansion of immunostimulatory dendritic cells among the myeloid progeny of human CD34+ bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF-alpha
186. CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF alpha
187. Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy
188. Fibronectin upregulates in vitro generation of dendritic Langerhans cells from human cord blood CD34+ progenitors
189. Drammatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: Multiple dendritic cell subpopulations identified
190. Increased circulating dendritic cells in healthy human volunteers following administration of FLT3 ligand alone or in combination with GM-CSF or G-CSF
191. Flt3 ligand induces tumor regression and antitumor immune responses in vivo
192. FLT3 ligand administration inhibits tumor growth in murine melanoma and lymphoma
193. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
194. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
195. Eradication of established murine tumors using a novel cell-free vaccine: Dendritic cell-derived exosomes
196. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo
197. Retroviral transduction of human dendritic cells with a tumor-associated antigen gene
198. High efficiency adenovirus-mediated gene transfer to human dendritic cells
199. Largescale feasibility of gene transduction into human CD34+ cell derived-dendritic cells by polication/adenoviral complex
200. Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells
201. Vaccinia virus: A tool for research and vaccine development
202. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses
203. CD34(+) acute myeloid and lymphoid leukemic blasts can be induced to differentiate into dendritic cells
204. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia
205. Ex vivo generation of bcr/abl positive dendritic cells from CD34+ chronic myeloid leukemia cells
206. Vaccine therapy for cancer
207. Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells
208. Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: A clinical phase I study
209. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo
210. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
211. Immunization with a tumor-cell-lysate-loaded autologous-antigen-presenting-cell-based vaccine in melanoma
212. The role of interleukin-2, interleukin-12, and dendritic cells in cancer therapy
213. Active specific immunotherapy for stage II and stage III human colon cancer: A randomised trial
214. Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen
215. Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cycotoxicity
216. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen
217. Phase I trial of dendritic cell-based immunotherapy with APC8015 for hormone-refractory prostate cancer (HRPC)
218. Monitoring of prostate-specific membrane antigen (PSMA)-specific immune response and prostate markers in a phase II clinical trial with patients infused with dendritic cells pulsed with PSMA-derived peptides
219. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen
220. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone
221. Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: An outpatient multicenter trial
222. Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor
223. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells
224. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
225. Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies: Correlation with diagnosis and disease status
226. Generation of T cell clones binding F(ab')2 fragments of the idiotypic immunoglobulin in patients with monoclonal gammopathy
227. Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies
228. Idiotype-specific T lymphocytes in monoclonal gammopathies: Evidence for the presence of CD4+ and CD8+ subsets
229. T cells recognize the VH complementarity-determining region 3 of the idiotypic protein of B cell non-Hodgkin's lymphoma
230. Immunogenicity and cross-reactivity with idiotypic IgA of VH CDR3 peptide in multiple myeloma
231. T-cell-epitope mapping of the idiotypic monoclonal IgG heavy and light chains in multiple myeloma
232. Idiotypic vaccination in B-cell malignancies
233. Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkin's lymphoma
234. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma
235. High-dose sequential chemoradiotherapy in multiple myeloma: Residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting
236. Cytokine-based tumor cell vaccine is equally effective against parental and isogenic multidrug-resistant myeloma cells: The role of cytotoxic T lymphocytes
237. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses
238. Idiotype vaccination in human myeloma: Generation of tumor-specific immune responses after high-dose chemotherapy
239. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells
240. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
241. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma-a feasibility study
242. Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime the immune system in multiple myeloma
243. Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma
244. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma
245. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: Immunological and clinical aspects
246. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells
247. Follicular lymphomas can be induced to present alloantigen efficiently: A conceptual model to improve their tumor immunogenicity
248. CD40-activated human B cells: An alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy
249. Adenovirus vector-based purging of multiple myeloma cells
250. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor
251. Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient
252. Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone
253. Genes encoding tumor-specific antigens are expressed in human myeloma cells
254. Multicolor spectral karyotyping identifies new recurring breakpoints and translocations in multiple myeloma
255. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3
256. Idiotypic DNA vaccines against B-cell lymphoma
257. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma
258. DNA immunization induces protective immunity against B-cell lymphoma
259. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma
260. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity
261. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients
262. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse or chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease
263. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation
264. Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia
265. Cancer Vaccines. Once more unto the breach
266. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia
267. Immunization of patients with melanoma peptide vaccines: Immunologic assessment using the ELISPOT assay
268. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma
269. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes
270. The advent of the 'unpatients'
271. Cytokine gene therapy: Hopes and pitfalls
272. Inducing autoimmune disease to treat cancer
273. Prevention of cancer in the next millenium: Report of the Chemoprevention Working Group to the American Association for Cancer Research
274. Ueber den jetzigen Stand der Karzinomforschung